leisure time -WSS

leisure time

author：hotspot 2025-08-12 09:12:27 - browse：7969

Adam's take main illustration — Molly Ferguson/STAT

Happy Groundhog Day eve. Some takes and thoughts on Bluebird Bio’s quest for gene therapy profits, a reality check on Vertex’s highly touted pain drug, and more ADC investor FOMO.

Bluebird and the case for gene therapy profits

Genetic treatments that are potential cures for inherited diseases are a huge medical advance, but can these transformational (and expensive) products become a profitable business? I’m not sure anyone knows yet for sure, but pay attention to Bluebird Bio over the next year for some clues.

Bluebird is unique among the biotech and pharma companies selling gene therapies (or CRISPR-based medicines) today because it has no other marketed products. With the recent approval of Lyfgenia for sickle cell disease (cost: $3.1 million), Bluebird sells three gene therapies. The other products are Zynteglo for beta thalassemia ($2.8 million) and Skysona for cerebral adrenoleukodystrophy ($3 million). It’s a pure-play commercial gene therapy business. It’s not even trying to develop additional gene therapies currently. R&D expenses are tied to gathering long-term data on its existing products.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： What PEPFAR has meant on the ground in Ukraine

WSS

What causes an itch? Researchers may have solved the mystery

NIH nominee Bertagnolli will get October confirmation hearing

A rare thyroid diagnosis led to unexpected, all

FDA needs staff influx to meet gene therapy needs, Marks says

Chemotherapy shortages won’t get better under Biden’s latest plan

NIH nominee Bertagnolli will get October confirmation hearing

Wikipedia

leisure time

Bluebird and the case for gene therapy profits

explore

Continuity nursing helped my family in our darkest PICU moments

Humana sues Biden admin over Medicare Advantage audit rule

The high cost of giving birth even with insurance

Listen: Biogen's potential pivot, & Illumina's next chapter

Continuity nursing helped my family in our darkest PICU moments

FDA needs staff influx to meet gene therapy needs, Marks says

State Dept. review finds Biden bears some blame for Afghanistan failures

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

Hepatitis C has a cure — but many Americans still lack access to it

Roche to buy Carmot Therapeutics, developer of obesity drugs

Wikipedia

Congenital heart disease patients face new threat of heart failure

CMS should re

Spinal cord stimulation reduces pain in amputees, study finds

Advances in CAR

Snackable artificial intelligence, expert AI, and the pharma industry

Pharma patents targeted by Biden in move to slash drug prices

hotspot

hotspot

hotspot

leisure time